Johnson & Johnson Reports Strong Three-Year Data for TREMFYA in

Johnson & Johnson (JNJ) reported that its drug Tremfya achieved 94% clinical remission in Crohn’s disease patients over three years in phase 3 trials. JNJ has a 1.95% dividend yield, 55% payout ratio, and 4.9% 3-year dividend growth. The stock is 35.7% above its GF Value of $194.33, trading at $263.73. JNJ has a GF Score of 83, indicating strong financial health, but insiders have been net sellers.

Johnson & Johnson presented three-year data from Phase 3 GALAXI 2 and 3 studies, showing durable efficacy and consistent safety for TREMFYA in Crohn's disease. Results indicate high rates of clinical and endoscopic remission for both dosing regimens. TREMFYA is approved for Crohn's disease and other inflammatory conditions.

Johnson & Johnson reported Phase 3 data showing TREMFYA achieved 28% and 27% combined fistula remission in Crohn's disease patients, vs. 10% for placebo. Subgroup analyses showed consistent results across different patient types. The study was presented at the ACG 2026 meeting.

Johnson & Johnson (JNJ) reported Phase 3 data showing Tremfya achieved 28% and 27% fistula remission in Crohn's patients at Week 24, versus 10% for placebo. Subgroup analyses showed higher remission rates in specific patient groups. Tremfya is approved for Crohn's disease in the U.S. The data was presented at the American College of Gastroenterology 2026 meeting.

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

Johnson & Johnson reported 3-year data from GALAXI 2 and 3 studies showing TREMFYA achieved up to 94% clinical remission and 61% endoscopic remission in Crohn's patients. 88% maintained 90-day corticosteroid-free remission. Safety profile remained consistent. Data presented at ACG 2026.